Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has garnered an average rating of “Moderate Buy” from eighteen research firms covering the company, according to data from Marketbeat. The analysis reveals that one analyst has recommended selling the stock, one has given a hold rating, while the remaining sixteen analysts endorse a buy recommendation. The average twelve-month price target set by brokers monitoring Ultragenyx is approximately $65.76.
Recent reports from various financial institutions have influenced the stock’s outlook. On January 21, 2024, Weiss Ratings reissued a “sell (e+)” rating on Ultragenyx shares. Earlier, on January 2, 2024, Bank of America adjusted their target price from $72.00 to $58.00, maintaining a buy rating on the stock. Additionally, Wells Fargo & Company lowered its price target from $65.00 to $45.00, assigning an “overweight” rating in their report dated December 30, 2023.
JPMorgan also made adjustments, cutting its price target from $120.00 to $74.00 while sustaining an overweight rating, indicating confidence in Ultragenyx’s long-term potential despite near-term challenges.
Investor Activity and Stock Performance
Institutional investors have significantly influenced Ultragenyx’s market dynamics. Notably, UBS Asset Management increased its holdings in the company by 14.8%, acquiring an additional 29,984 shares in the first quarter, bringing its total to 232,360 shares, valued at approximately $8.41 million. Envestnet Asset Management also boosted its stake by 6.0%, adding 1,698 shares during the second quarter.
As of Tuesday, Ultragenyx shares traded at $21.34, reflecting a decline of 1.7%. The stock has experienced considerable volatility, with a 52-week low of $18.41 and a high of $42.37. The company’s market capitalization stands at about $2.06 billion, with a price-to-earnings ratio of -3.65 and a beta of 0.16.
In its latest quarterly earnings report, released on February 12, 2024, Ultragenyx reported an earnings per share (EPS) of ($1.29), falling short of the consensus estimate of ($1.20) by $0.09. The company generated $207.28 million in revenue for the quarter, surpassing analyst expectations of $199.60 million. This represents a year-over-year revenue increase of 25.5%.
Recent Challenges and Developments
Ultragenyx faces potential legal hurdles as multiple law firms have announced a securities class action concerning purchases made between August 3, 2023, and December 26, 2025. These firms are seeking lead plaintiffs with a deadline set for April 6, 2026. This situation raises legal and headline risks, likely putting pressure on the stock in the short term.
Despite these challenges, there is a sense of optimism surrounding Ultragenyx’s recent phase-3 trial results for its gene therapy, DTX301, which demonstrated an approximate 18% reduction in ammonia levels compared to a placebo. This trial result is significant for the company as it moves closer to regulatory approval and potential commercialization.
Founded in 2010 and headquartered in Novato, California, Ultragenyx Pharmaceutical focuses on developing therapies for rare genetic disorders. The company’s product portfolio includes treatments such as Crysvita for X-linked hypophosphatemia and Mepsevii for mucopolysaccharidosis VII. With a commitment to addressing unmet medical needs, Ultragenyx continues to leverage both in-house research and collaborations to advance its pipeline.
As the company navigates these developments, analysts will continue to monitor its performance closely, particularly in light of recent market activity and ongoing clinical trials.
